Literature DB >> 25039711

Homozygous IL36RN mutation and NSD1 duplication in a patient with severe pustular psoriasis and symptoms unrelated to deficiency of interleukin-36 receptor antagonist.

R Carapito1, B Isidor, N Guerouaz, M Untrau, M Radosavljevic, E Launay, E Cassagnau, C Frenard, H Aubert, B Romefort, C Le Caignec, L Ott, N Paul, S Barbarot, S Bahram.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25039711     DOI： 10.1111/bjd.13261

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

Review 1.  Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA.

Authors:  Francisco Gómez-García; Juan L Sanz-Cabanillas; Isabel Viguera-Guerra; Beatriz Isla-Tejera; Antonio Vélez-García Nieto; Juan Ruano
Journal:  Dermatol Ther (Heidelb)       Date:  2018-11-03

2.  Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin.

Authors:  Edwin Cuperus; Rosanne Koevoets; Jasper J van der Smagt; Johan Toonstra; Marlies de Graaf; Joost Frenkel; Suzanne G M A Pasmans
Journal:  JAAD Case Rep       Date:  2018-02-02

3.  Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

Authors:  Rajkumar Ganesan; Ernest L Raymond; Detlev Mennerich; Joseph R Woska; Gary Caviness; Christine Grimaldi; Jennifer Ahlberg; Rocio Perez; Simon Roberts; Danlin Yang; Kavita Jerath; Kristopher Truncali; Lee Frego; Eliud Sepulveda; Priyanka Gupta; Su-Ellen Brown; Michael D Howell; Keith A Canada; Rachel Kroe-Barrett; Jay S Fine; Sanjaya Singh; M Lamine Mbow
Journal:  MAbs       Date:  2017-07-20       Impact factor: 5.857

4.  Genetic polymorphism of IL36RN in Han patients with generalized pustular psoriasis in Sichuan region of China: A case-control study.

Authors:  Zhongtao Li; Qianyi Yang; Sheng Wang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.